FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
Seek expert advice.
- induction treatment for most patients with ANCA associated vasculitis (AAV) should be with
cyclophosphamide or rituximab and glucocorticoids
- AAV should be considered to be a chronic disease needing longterm
- rituximab should be considered as an alternative induction
agent for those at high risk of infertility and infection
- mortality remains high, and late death is due to
cardiovascular disease, infection (secondary to treatment) and
- role of serial ANCA measurement in determining
treatment during remission remains controversial
current evidence suggests patients in whom ANCA remains
present or rises more than fourfold are at greater risk of relapse.
- Davies DJ. Small vessel vasculitis. Cardiovascular Pathology 2005; 14 (6):
- ARC Autumn 2012. Topical Reviews - ANCA-associated vasculitis; 1:1-12.
- Yates A, Watts R. ANCA-associated vasculitis. Clinical Medicine 2017 Vol 17, No 1: 60–4
Last edited 05/2020 and last reviewed 05/2020